Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Significant Decrease in Short Interest

Key Points

• Short interest dropped to 7,193,959 shares as of March 31, a 33.6% decline from March 15, equal to 3.1% of shares outstanding and a short-interest ratio of 3.4 days.
• Institutional buying increased, led by Millennium Management (now 2,087,398 shares after adding 512,842), with institutional investors owning 31.82% of the company.
• AMRX trades near $12.83 with a 52‑week range of $7.01–$15.42 and a market cap of about $4.04 billion; analysts have a consensus rating of Moderate Buy and a $14.20 target (Truist raised its target to $17).

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) saw a significant drop in short interest in March. As of March 31st, there was short interest totaling 7,193,959 shares, a drop of 33.6% from the March 15th total of 10,840,612 shares. Currently, 3.1% of the shares of the stock are short sold. Based on an average trading volume of 2,124,225 shares, the short-interest ratio is currently 3.4 days.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Several institutional investors have recently bought and sold shares of AMRX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Amneal Pharmaceuticals by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company's stock valued at $793,000 after purchasing an additional 4,178 shares during the last quarter. Millennium Management LLC lifted its position in Amneal Pharmaceuticals by 32.6% during the first quarter. Millennium Management LLC now owns 2,087,398 shares of the company's stock valued at $17,492,000 after purchasing an additional 512,842 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Amneal Pharmaceuticals in the 1st quarter worth about $244,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Amneal Pharmaceuticals by 5.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company's stock worth $2,807,000 after acquiring an additional 16,536 shares during the last quarter. Finally, Creative Planning lifted its holdings in shares of Amneal Pharmaceuticals by 61.9% in the 2nd quarter. Creative Planning now owns 23,896 shares of the company's stock worth $193,000 after acquiring an additional 9,136 shares during the last quarter. Institutional investors own 31.82% of the company's stock.

Amneal Pharmaceuticals Stock Up 2.3%

AMRX stock opened at $12.83 on Tuesday. Amneal Pharmaceuticals has a 52 week low of $7.01 and a 52 week high of $15.42. The company has a fifty day simple moving average of $13.32 and a two-hundred day simple moving average of $12.40. The firm has a market capitalization of $4.04 billion, a P/E ratio of 55.79 and a beta of 1.32.

Wall Street Analyst Weigh In

Several research firms recently weighed in on AMRX. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Truist Financial raised their target price on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Monday, March 2nd. Finally, Zacks Research cut shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 6th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $14.20.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.